Home › Companies › ADMA Biologics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and ADMA Biologics, Inc.’s Form 8-K, filed June 2, 2026 (Item 5.07 on EDGAR). Page generated October 13, 2026.
Meeting of June 2, 2026: 4 items on ADMA Biologics, Inc.’s Form 8-K, filed June 2, 2026: 4 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided · This season’s results screens
Proxy season: 2024-2025 2025-2026
Explore ADMA Biologics, Inc. in the interactive database Compare manager voting policies
These tallies are ADMA Biologics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 2, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Alison C. Finger | 156,849,830 | -- | -- | 19,376,842 | 23,040,875 | 89% | Not verified | — |
| Elect Director: Eduardo Rene Salas | 171,947,523 | -- | -- | 4,279,149 | 23,040,875 | 98% | Not verified | — |
| 2. The ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; and | 198,655,040 | 329,056 | 283,451 | -- | -- | 99.8% | Not verified | — |
| 3. The approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers ("Say-on-Pay") | 168,169,866 | 7,730,690 | 326,116 | -- | 23,040,875 | 96% | Not verified | — |
Source: ADMA Biologics, Inc., Form 8-K, filed with the SEC on June 2, 2026 — read the filing on EDGAR.
Each item below shows how the 356 asset managers that disclosed a ADMA Biologics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: To elect the following Class I directors for a term expiring at the 2029 Annual Meeting of Stockholders or until their successors are duly elected and qualified: Alison C. Finger
ADMA Biologics, Inc.’s own tally for this item (“Elect Director: Alison C. Finger”): 156,849,830 for, 19,376,842 withheld, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 103 asset managers below reported 91,621,277 for, 10,396,856 withheld, 153 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 25,918,010 | 0 | 0 | 427,111 | For |
| Vanguard | 20,445,936 | 0 | 153 | 37,231 | For |
| Capital Group | 11,738,761 | 0 | 0 | 0 | For |
| State Street | 8,946,809 | 0 | 0 | 0 | For |
| Fidelity | 5,746,339 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 4,051,804 | Withhold |
| American Century | 3,547,215 | 0 | 0 | 0 | For |
| Invesco | 2,561,022 | 0 | 0 | 0 | For |
| Charles Schwab | 1,938,807 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 1,589,164 | Withhold |
| Nuveen | 0 | 0 | 0 | 1,439,853 | Withhold |
| Federated Hermes | 1,320,457 | 0 | 0 | 0 | For |
| Dimensional | 1,299,905 | 0 | 0 | 0 | For |
| Putnam | 0 | 0 | 0 | 1,167,273 | Withhold |
| Allspring | 688,578 | 0 | 0 | 0 | For |
| Jackson National | 537,981 | 0 | 0 | 0 | For |
| Equitable | 329,728 | 0 | 0 | 187,370 | Mixed |
| Bridge Builder Trust | 495,279 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 489,842 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 375,073 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 0 | 364,267 | Withhold |
| World Funds Trust | 350,000 | 0 | 0 | 0 | For |
| First Trust | 348,223 | 0 | 0 | 0 | For |
| Brighthouse | 82,394 | 0 | 0 | 250,898 | Mixed |
| Russell Investments | 0 | 0 | 0 | 292,066 | Withhold |
Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To elect the following Class I directors for a term expiring at the 2029 Annual Meeting of Stockholders or until their successors are duly elected and qualified: Eduardo Rene Salas
ADMA Biologics, Inc.’s own tally for this item (“Elect Director: Eduardo Rene Salas”): 171,947,523 for, 4,279,149 withheld, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 103 asset managers below reported 99,786,889 for, 2,247,993 withheld, 39 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 26,345,121 | 0 | 0 | 0 | For |
| Vanguard | 20,483,281 | 0 | 39 | 0 | For |
| Capital Group | 11,738,761 | 0 | 0 | 0 | For |
| State Street | 8,946,809 | 0 | 0 | 0 | For |
| Fidelity | 5,746,339 | 0 | 0 | 0 | For |
| TIAA | 4,051,804 | 0 | 0 | 0 | For |
| American Century | 3,547,215 | 0 | 0 | 0 | For |
| Invesco | 2,561,022 | 0 | 0 | 0 | For |
| Charles Schwab | 1,938,807 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 1,589,164 | Withhold |
| Nuveen | 1,439,853 | 0 | 0 | 0 | For |
| Federated Hermes | 1,320,457 | 0 | 0 | 0 | For |
| Dimensional | 1,299,905 | 0 | 0 | 0 | For |
| Putnam | 1,167,273 | 0 | 0 | 0 | For |
| Allspring | 688,578 | 0 | 0 | 0 | For |
| Jackson National | 537,981 | 0 | 0 | 0 | For |
| Equitable | 329,728 | 0 | 0 | 187,370 | Mixed |
| Bridge Builder Trust | 495,279 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 489,842 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 375,073 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 364,267 | 0 | 0 | 0 | For |
| World Funds Trust | 350,000 | 0 | 0 | 0 | For |
| First Trust | 348,223 | 0 | 0 | 0 | For |
| Brighthouse | 82,394 | 0 | 0 | 250,898 | Mixed |
| Russell Investments | 292,066 | 0 | 0 | 0 | For |
Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.
Combines 9 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.
ADMA Biologics, Inc.’s own tally for this item (“3. The approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers ("Say-on-Pay")”): 168,169,866 for, 7,730,690 against, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 26,345,121 | 0 | 0 | 0 | For |
| Vanguard | 20,483,296 | 20 | 2 | 0 | For |
| Capital Group | 11,738,761 | 0 | 0 | 0 | For |
| State Street | 8,946,809 | 0 | 0 | 0 | For |
| Fidelity | 5,746,339 | 0 | 0 | 0 | For |
| TIAA | 4,051,804 | 0 | 0 | 0 | For |
| American Century | 3,547,215 | 0 | 0 | 0 | For |
| Invesco | 0 | 2,561,022 | 0 | 0 | Against |
| Charles Schwab | 1,938,807 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,589,164 | 0 | 0 | 0 | For |
| Nuveen | 1,439,853 | 0 | 0 | 0 | For |
| Federated Hermes | 1,320,457 | 0 | 0 | 0 | For |
| Dimensional | 1,299,905 | 0 | 0 | 0 | For |
| Putnam | 1,167,273 | 0 | 0 | 0 | For |
| Allspring | 688,578 | 0 | 0 | 0 | For |
| Jackson National | 537,981 | 0 | 0 | 0 | For |
| Equitable | 517,098 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 495,279 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 489,842 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 375,073 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 364,267 | 0 | 0 | 0 | For |
| World Funds Trust | 350,000 | 0 | 0 | 0 | For |
| First Trust | 348,223 | 0 | 0 | 0 | For |
| Brighthouse | 284,727 | 0 | 48,565 | 0 | Mixed |
| Russell Investments | 292,066 | 0 | 0 | 0 | For |
Fund voting reports, all 102 managers: 99,143,541 for, 2,842,811 against, 48,567 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Research Global Investors | 11,738,761 | 0 | 0 | 0 | For |
| BlackRock | 9,326,781 | 3,111 | 0 | 0 | For |
| Nuveen | 6,203,477 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 5,830,605 | 0 | 0 | 0 | For |
| State Street | 4,588,040 | 0 | 0 | 0 | For |
| Caligan Partners LP | 4,109,865 | 0 | 0 | 0 | For |
| American Century | 3,968,259 | 0 | 0 | 0 | For |
| Invesco | 0 | 3,308,646 | 0 | 0 | Against |
| B Group, Inc. | 3,198,949 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,551,027 | 0 | 0 | 0 | For |
| Charles Schwab | 2,089,701 | 0 | 0 | 0 | For |
| Ranger Investment Management, L.P. | 2,055,615 | 0 | 0 | 0 | For |
| Vanguard | 2,010,052 | 0 | 0 | 0 | For |
| Northern Trust | 1,994,917 | 0 | 0 | 0 | For |
| Federated Hermes | 1,848,708 | 0 | 0 | 0 | For |
| Putnam | 1,802,412 | 0 | 0 | 0 | For |
| Fundsmith LLP | 0 | 1,649,493 | 0 | 0 | Against |
| Duquesne Family Office LLC | 1,545,610 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 1,501,886 | 0 | 0 | 0 | For |
| Point72 | 1,490,651 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 1,392,626 | 0 | 0 | 0 | For |
| MetLife Investment Management, LLC | 1,376,129 | 0 | 0 | 0 | For |
| National Philanthropic Trust | 0 | 0 | 0 | 0 | Not Voted |
| JUPITER ASSET MANAGEMENT LTD | 924,183 | 0 | 0 | 0 | For |
| Renaissance | 814,602 | 0 | 0 | 0 | For |
Institutional-manager reports, all 281 managers: 90,113,699 for, 6,045,231 against, 65,874 abstained, 1,199,338 not voted. Showing the 25 largest; see all in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
ADMA Biologics, Inc.’s own tally for this item (“2. The ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; and”): 198,655,040 for, 329,056 against, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 103 asset managers below reported 101,986,352 for, 2 against, 48,567 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 26,345,121 | 0 | 0 | 0 | For |
| Vanguard | 20,483,316 | 2 | 2 | 0 | For |
| Capital Group | 11,738,761 | 0 | 0 | 0 | For |
| State Street | 8,946,809 | 0 | 0 | 0 | For |
| Fidelity | 5,746,339 | 0 | 0 | 0 | For |
| TIAA | 4,051,804 | 0 | 0 | 0 | For |
| American Century | 3,547,215 | 0 | 0 | 0 | For |
| Invesco | 2,561,022 | 0 | 0 | 0 | For |
| Charles Schwab | 1,938,807 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,589,164 | 0 | 0 | 0 | For |
| Nuveen | 1,439,853 | 0 | 0 | 0 | For |
| Federated Hermes | 1,320,457 | 0 | 0 | 0 | For |
| Dimensional | 1,299,905 | 0 | 0 | 0 | For |
| Putnam | 1,167,273 | 0 | 0 | 0 | For |
| Allspring | 688,578 | 0 | 0 | 0 | For |
| Jackson National | 537,981 | 0 | 0 | 0 | For |
| Equitable | 517,098 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 495,279 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 489,842 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 375,073 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 364,267 | 0 | 0 | 0 | For |
| World Funds Trust | 350,000 | 0 | 0 | 0 | For |
| First Trust | 348,223 | 0 | 0 | 0 | For |
| Brighthouse | 284,727 | 0 | 48,565 | 0 | Mixed |
| Russell Investments | 292,066 | 0 | 0 | 0 | For |
Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 232,288,977 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 11.34% |
| 2 | Vanguard | 8.82% |
| 3 | Capital Group | 5.05% |
| 4 | State Street | 3.85% |
| 5 | Fidelity | 2.47% |
| 6 | TIAA | 1.74% |
| 7 | American Century | 1.53% |
| 8 | Invesco | 1.10% |
| 9 | Charles Schwab | 0.83% |
| 10 | T. Rowe Price | 0.68% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Capital Research Global Investors | 5.05% |
| 2 | BlackRock | 4.02% |
| 3 | Nuveen | 2.67% |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 2.51% |
| 5 | State Street | 1.98% |
| 6 | Caligan Partners LP | 1.77% |
| 7 | American Century | 1.71% |
| 8 | Invesco | 1.42% |
| 9 | B Group, Inc. | 1.38% |
| 10 | T. Rowe Price | 1.10% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 15.86% | 13F |
| Vanguard Group | 8.98% | 13F |
| State Street | 6.06% | 13F |
| Citadel Advisors | 2.69% | 13F |
| Dimensional Fund Advisors | 2.15% | 13F |
| Invesco | 1.77% | 13F |
| Point72 | 1.42% | 13F |
| Goldman Sachs | 1.21% | 13F |
Percentages above are of 232,288,977 shares outstanding, as reported by ADMA Biologics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ADMA Biologics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 13, 2026; a live search always shows the current data.
At ADMA Biologics, Inc.'s shareholder meeting held June 2, 2026, in the 2025-2026 proxy season, 356 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 1,745 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ADMA Biologics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 2, 2026.
ADMA Biologics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.